INFLUENCE OF BIOLOGICAL THERAPY IN PATIENTS WITH NON-SPECIFIC ULCERATIVE COLLITIS WITH PRESENT JOINT DISEASES
DOI:
https://doi.org/10.24144/2077-6594.3.2.2020.213726Keywords:
nonspecific ulcerative colitis, joint diseases, tofacitinibAbstract
The purpose of the study is to evaluate the effect of tofacitinib on the changes of laboratory, clinical and endoscopic indicators in patients with UC and concomitant joint diseases.
Materials and methods. The study included 74 patients with a diagnosis of moderate to severe UC. Their age were 18 to 75 years, with a disease duration at least 6 months. Patients were divided into 2 groups. Group I included patients with UC, who received standard therapy with budesonide 9 mg 1 time per day (BUD; n = 34), group II – patients were treated with Tofacitinib 10 mg 2 times per day ("Equinus", "Xelys") (TOF; n = 40).
Results. As a result of the treatment in the TOF group, the indicators of WBC and CRP decreased, compared with similar indicators before treatment (from 13.6±2.4*109/l and 14.0±1.4 mg/l to 10.6±1.2*109/l and 11.0±2.1 mg/l, respectively, p<0.05). The hemoglobin level in this group increased (from 104.2±9.2 g/l to 124.1±8.6 g/l, p<0.05). In patients who received budesonide, were no statistically significant changes in laboratory indicators. In the TOF group, the VAS index decreased in comparison with the same indicator before treatment (from 8.6±0.2 cm to 6.0±0.3 cm, p<0.05), which was not observed in the BUD group. Also, in the TOF group, the CAI and EAI indices decreased in comparing to those before treatment (from 9.68±0.34 and 9.52±0.56 to 5.0±0.28 and 6.58±0.44 respectively, p<0.05), in contrast to the BUD group, there were no statistically probable changes in activity indices.
Conclusions. Tofacitinib in the treatment of patients with nonspecific ulcerative colitis of moderate and severe severity with concomitant joint diseases showed better clinical, laboratory and endoscopic indicators if compare with budesonide treatment.
References
Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management Mayo Clin Proc. 2014; 89(11):1553-1563.
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort / S. Vavricka, G. Rogler, C. Gantenbein [et al.] // Inflamm Bowel Dis. – 2015. – № 21(8). –P. 1794-1800.
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease / M. Harbord, V. Annesse, S. Vavricka [et al.] // Journal of Crohn’s and Colitis. – 2015. – № 10 (3). – P. 239-254.
Sieper, J. Axial spondyloarthritis / J. Sieper, D. Poddubnyy // Lancet. – 2017. – № 390 (10089). – P. 73-84.
Management of patients with inflammatory bowel disease and spondyloarthritis / L. Pouillon, P. Bossuyt, J. Vanderstukken [et al.] // Expert Review Of Clinical Pharmacology. – 2017. – № 10(12). – P. 1363-1374.
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ ecco-jcc/jjx133.
Tofacitinib for the treatment of ulcerative colitis. Izzo R, Bevivino G, Monteleone G.Expert Opin Investig Drugs. 2016 Aug;25(8):991-7. doi: 10.1080/13543784.2016.1189900. Epub 2016 May 30.
